chronic spontaneous urticaria

BOSTON, July 27, 2026 Bambusa Therapeutics announced encouraging preliminary proof-of-concept results from its ongoing global Phase 1 clinical trial...

HAMPTON, N.J., July 21, 2026 Celldex announced topline results from its Phase 2 clinical trial evaluating barzolvolimab in patients...

BASEL, Switzerland, June 8, 2026 Novartis announced the presentation of data from 10 scientific abstracts at the European Academy...

PISCATAWAY, N.J., June 4, 2026 Kashiv BioSciences has announced a significant regulatory milestone with the validation and acceptance by...

BRISBANE, Calif., May 14, 2026 Nurix Therapeutics presented new preclinical and Phase 1 translational data at the Society for...

Tarrytown, New York, USA & Paris, France – April 22, 2026 In a significant advancement for pediatric immunology and...

TARRYTOWN, N.Y. and PARIS, April 13, 2026 Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved...

Hyderabad, India, April 7, 2026 Phase 3 Trial Confirms Biosimilar Equivalence In a significant milestone for biosimilar drug development,...

Hampton, N.J., USA | March 27, 2026 Celldex Therapeutics reported compelling results from Phase 2 clinical trials of barzolvolimab,...

JENA, Germany, December 11, 2025 — InflaRx N.V. announced that the World Health Organization (WHO) has granted the International...